A*STAR

Group Leader, Oligonucleotides Chemistry

A*STAR
ResearchSingaporeOnsitePosted 1 month ago

About the role

Group Leader, Oligonucleotides Chemistry role based on the published job description. Key responsibilities and requirements were extracted directly from the posting for quick review.

ResearchOnsite

Key Responsibilities

  • About NATi The Nucleic Acid Therapeutics Initiative (NATi), hosted by A*STAR, is Singapore's national platform dedicated to advancing RNA-based medicines and revolutionizing drug and vaccine development.
  • NATi's mission is to establish Singapore as a globally recognized hub of excellence in nucleic acid therapeutics research, clinical translation, and commercialisation.
  • NATi focuses on key RNA modalities such as antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and messenger RNA (mRNA).
  • To drive this vision, NATi is building a biotech-like translational engine focused on asset and technology development spanning discovery to clinical development.
  • Position Overview The Group Leader, Oligonucleotides Chemistry will oversee NATi's oligonucleotide chemistry capabilities spanning pre-clinical synthesis, separation, and analytical characterization workflows.
  • Beyond establishing robust SPOS-based workflows, this role is instrumental in expanding the oligonucleotides platform into next-generation chemistries, novel constructs, and differentiated oligonucleotide formats.

Requirements

  • Qualifications & Experience
  • A doctorate degree in Chemistry, Chemical Biology, Organic/Medicinal Chemistry, or a related field.
  • A minimum of 7+ (Senior Scientist), 10+ (Principal Scientist), 13+ (Associate Director) years of hands-on modern synthetic chemistry methods particularly in nucleosides, nucleotides, and oligonucleotide synthesis, purification, and analysis in pharmaceutical or biotechnology settings.
  • Extensive hands-on experience with modern SPOS instrumentation (e.g., MerMade 192X/12, ÄKTA OligoSynth), purification systems (e.g., ÄKTA Avant/Pure, tangential flow filtration), and analytical platforms (e.g., UPLC, LC/MS, HRMS), and lyophilisers.
  • Demonstrated ability to build or expand oligonucleotide chemistry capabilities, integrate emerging chemistries, and develop robust platform workflows.
  • Experience managing or collaborating with CROs, including tech transfer, oversight, and governance of outsourced synthesis or analysis activities.